Guillermo Garcia-Manero, MD

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.

Dr Garcia-Manero discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress.

Key opinion leaders summarize their main insights and key takeaways from the EHA 2024 conference regarding advances in lower-risk myelodysplastic syndrome treatment.

The expert panel explores the future landscape of lower-risk myelodysplastic syndrome treatment, considering recent approvals and emerging clinical data.

Key opinion leaders (KOLs) examine real-world evidence and draw on their clinical experiences to inform their practice, discussing real-world dose escalations and key insights gained from practical application.

Medical professionals deliberate on patient selection criteria for second-line imetelstat treatment in lower-risk myelodysplastic syndromes, incorporating findings from the IMerge study into their considerations.

Medical experts discuss sequencing strategies for second-line and later treatments in lower-risk myelodysplastic syndromes, examining how recent data, including insights from the MEDALIST trial, influence treatment selection and sequencing decisions.

Medical experts explore alternative treatment options for lower-risk myelodysplastic syndrome (LR-MDS) patients who are not suitable candidates for first-line luspatercept therapy.

Key opinion leaders evaluate the safety profiles of available frontline treatments for patients with lower-risk myelodysplastic syndromes, including observed adverse reactions.

Medical professionals examine the utilization patterns of luspatercept in lower-risk myelodysplastic syndromes (LR-MDS) and their impact on patient treatment strategies.

Experts in lower-risk myelodysplastic syndromes analyze and interpret the comparative biomarker data on ring sideroblasts in LR-MDS patients from the COMMANDS study.

The panel examines the COMMANDS trial results, focusing on luspatercept's effects across erythroid, neutrophil, and platelet lineages and their implications for treatment decisions, while also exploring how genomic factors and mutational burden influence the drug's clinical outcomes in lower-risk myelodysplastic syndromes.

The aim of this study is to describe the demographic, clinical, and treatment characteristics of patients with LRMDS who were managed by physicians at Florida Cancer Specialists & Research Institute (FCS) and treated with ESAs, and to determine the proportion of LR-MDS patients who experience ESA failure and describe treatment patterns following ESA failure.

The experts examine the COMMANDS trial, which assessed luspatercept in lower-risk myelodysplastic syndrome patients, detailing the trial's design, participant groups, and key outcome measures.

A key opinion leader offers insights and analysis on the recently presented COMMANDS trial data from the European Hematology Association 2024 conference.

The experts examine the COMMANDS trial, which assessed luspatercept in lower-risk myelodysplastic syndrome patients, detailing the trial's design, participant groups, and key outcome measures.

The experts describe their strategies for selecting first-line treatments in lower-risk myelodysplastic syndrome patients, focusing on the key factors that inform their sequencing decisions in frontline therapy.

Key opinion leaders address various challenges linked to lower-risk myelodysplastic syndromes, with a focus on cytopenias.

The expert panel in hematology examines recent WHO and ICC guideline updates, evaluating their impact on the evolving treatment landscape for myelodysplastic syndromes.

Guillermo Garcia-Manero, MD, discusses the key efficacy findings from the phase 3 COMMANDS trial evaluating luspatercept-aamt in patients with myelodysplastic syndrome who were erythropoiesis-stimulating agent naïve and red blood cell transfusion dependent.

Guillermo Garcia-Manero, MD, discusses key efficacy and safety findings from the phase 3 COMMANDS trial (NCT03682536) of luspatercept-aamt (Reblozyl) vs epoetin alfa in patients with lower-risk myelodysplastic syndrome.

Experts close by summarizing key advances and remaining unmet needs across all MDS risk groups, and share their hopes for the future.

A brief discussion centered on MDS/MPN-RS-T overlap syndromes, considerations for diagnosis, available treatment options, and updates in the space.

The panelists touch on emerging data in the higher-risk MDS space, including updates presented at ASH 2022.

The panel turns their focus to higher-risk MDS, starting with a discussion of first- and second-line treatment options, followed by a third and final case presentation and discussion led by Dr Platzbecker.

Expert hematologic oncologists discuss updates from the ASH 2022 Annual Meeting on emerging therapies for lower-risk MDS.

Following the ASH 2022 Annual Meeting, experts in hematologic oncology review updated data for luspatercept in lower-risk MDS.

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

Experts summarize recent updates on other approved or emerging second-line therapies for lower-risk MDS.

Dr Komrokji presents key data updates from the MEDALIST trial on luspatercept in patients with lower-risk MDS that were presented at the 2022 European Hematology Association (EHA) Congress and the 2022 ASH Annual Meeting.